Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
Garcia-Manero G, Ooi M, Lao Z, Gill H, Abaza Y, Stahl M, Haque T, DeZern A, Greenberg P, Pelletier M, Singh A, Carreon D, Beaulieu V, Woo J. Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study. Blood 2023, 142: 3250. DOI: 10.1182/blood-2023-174642.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaCMML-specific prognostic scoring systemErythropoiesis-stimulating agentsDose-expansion partPrognostic scoring systemMyelodysplastic syndromeHypomethylating agentsLR-MDSEastern Cooperative Oncology Group performance statusIntermediate risk myelodysplastic syndromePredictive markers of efficacyDose of study treatmentInternational Prognostic Scoring SystemIL-18Colony-stimulating growth factorScoring systemAllogeneic hematopoietic transplantationBone marrow aspirate/biopsyPhase 1b studyProgression-free survivalTime to progressionPotential curative optionRisk myelodysplastic syndromesDuration of responseBone marrow assessment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply